Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

Veröffentlicht vonadmin

Baselga J, GГіmez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, PГЄgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, MelezГ­nkovГЎ H, Awada A.

http://www.ncbi.nlm.nih.gov/pubmed/23733761